test; quantitative variables were compared using the Mann-Whitney test. Post hoc statistical power was calculated for the main variables, ie, rate of anaphylaxis (0.84) and use of epinephrine (0.88).
Anaphylaxis can be defined as a serious allergic reaction that is rapid in onset and might cause death [1] . The incidence of pediatric anaphylaxis has been increasing in the last decade [2] , probably owing to the increasing frequency of food allergy, which remains the most important trigger of anaphylaxis in the pediatric population [3] .
Epinephrine is the medication of choice for the immediate treatment of anaphylaxis, and autoinjectors are the preferred method for administration in the community setting. Autoinjectors should be prescribed to patients with a history of anaphylaxis and a high probability of recurrence [1] . However, evidence has shown that many patients do not carry them or use them when needed [4] .
The purpose of this study was to describe the use of selfinjectable epinephrine for pediatric patients with food allergy.
We performed an observational, cross-sectional study of patients with food allergy attended in the Pediatric Allergy Unit of Hospital General Universitario Gregorio Marañón, Madrid, Spain between October and November 2016. Participants were invited to fill in an anonymous survey if they had already been diagnosed with food allergy. The survey included questions about reactions within the previous year and their management. Most of the questions were asked in a dichotomous format to facilitate responses and analysis. A detailed description of the survey has been published elsewhere [5] . The characteristics of the reactions were extracted from the clinical records by the investigators. This post hoc analysis includes only patients who had been prescribed an autoinjector, following recommendations by international guidelines [1] . The study was approved by the local ethics committee. Written informed consent was obtained from all participants.
The statistical analysis was performed with IBM SPSS Statistics Windows, Version 20.0 (IBM Corp). Qualitative variables are expressed as frequency and quantitative variables are expressed as median (IQR). Categorical variables were compared using the  2 test and Fisher exact Eighty-eight patients (85.4%) reported that they usually carried the devices with them. There were no statistically significant differences between patients who carried an autoinjector and those who did not with respect to sex (P=.5), age (P=.3), history of anaphylaxis (P=.3), triggers, or time since the diagnosis of food allergy (Table) .
Fifty-four patients (52.4%) had a food-triggered allergic reaction within the previous year; the reaction was anaphylaxis in 20 (19.4%). The frequency of reactions was similar in the autoinjector-carrying group and the nonautoinjector-carrying group (P=.9). However, anaphylaxis was significantly more common among the former (43.5% vs 0; P=.02) (Table) .
Only 10 of the patients who experienced a reaction received epinephrine (18.5%). There were no statistically significant differences between the patients who received epinephrine and those who did not with respect to sex (P=.3), age (P=.9), concomitant allergic diseases (P=.9), or triggers. Nevertheless, anaphylaxis was more common among those who had received epinephrine than among those who had not (100% vs 22.7%; P<.0001) (Supplementary Material).
Only 4 patients (7.4%) used their autoinjector to treat their reactions; 9 (16.7%) received epinephrine in a health center with a standard injection. Three patients (75%) who used their device received a second dose in a health center with a standard injection.
Avoidance is standard treatment for food allergy [1] . However, in our study, over half of the patients with a previous diagnosis of food allergy had had a reaction during the previous year, in many cases resulting in anaphylaxis. Studies of adverse food reactions in food-allergic people are scarce. One systematic review reported an incidence rate of self-reported anaphylaxis of 4.93/100 person-years [6] , which is lower than the 19.4% we recorded. However, comparison of these figures might be limited owing to methodological differences. Other studies have focused on the frequency of accidental exposure in children with known peanut allergy [7] and cow's milk allergy [8] (11.9% and 40%, respectively). As the latter figure was recorded in a pediatric allergy unit in Madrid, the population represented can be considered similar to ours.
In our study, most of the patients who were prescribed an autoinjector reported that they usually carried it with them. However, the device was used in a very small number of reactions. It is possible that some of them were mild and did not require treatment with epinephrine, as anaphylaxis was more common among patients who received epinephrine. However, previous studies have demonstrated that, regardless of severity, many patients do not have an epinephrine autoinjector readily available [9] . In fact, we found that fewer than half of the patients with anaphylaxis used epinephrine. Furthermore, most patients who received epinephrine for treatment of their reactions did not use their autoinjector. A survey among survivors of anaphylaxis showed similar results [4] . This observation has various explanations, including unavailability, inability to recognize anaphylaxis, severity of the reaction, inadequate training in the use and indications of the autoinjector, use of antihistamines, and concern about adverse effects [4, 10] .
Our study is subject to a series of limitations owing to its cross-sectional design, from which only associations, rather than causality, can be established. The data were collected in the pediatric allergy unit of an urban tertiary hospital, thus indicating a lack of external validity. Given that this is a post hoc analysis, some minor differences between groups may have gone undetected because of a potential lack of statistical power or recall bias. However, given the strength of the associations, it seems unlikely that this would alter the conclusions.
In summary, allergic reactions due to accidental exposure are not uncommon among children already diagnosed with food allergy. While many children report that they usually carry epinephrine, they rarely use it. Anaphylaxis in the community remains undertreated.
IgE-mediated sesame allergy affects 0.1%-2.8% of the population depending on genetic and environmental factors [1] . Affected patients present a wide spectrum of clinical manifestations that span from wheals to anaphylaxis [2] . In most instances, this allergy is persistent and rarely resolves spontaneously [3] . Currently, most patients with sesame allergy are instructed to avoid contact with foods containing the food allergen. However, studies have shown that contact with as little as 0.13 mg of sesame protein can trigger a reaction [4] , thus implying that food containing trace amounts of the antigen must be avoided. The development of methods aimed at desensitizing patients to sesame protein could provide nutritional safety for persons at risk.
A search based on the terms sesame, allergy, desensitization, and treatment revealed only 1 study in which the authors used multiple allergen desensitization to control the clinical manifestations of sesame allergy [5] . The diagnosis of sesame allergy was based on double-blind placebo-controlled challenge, which was positive in 24% of patients. The desensitization protocol was divided into 3 phases: an initial escalation day, home dosing, and a maintenance phase. Up to 5 distinct antigens were administered orally beginning with an individual dose of 0.1 mg, which was increased to a maximum of 5.0 mg on the initial escalation day. During the home-dosing phase, patients took a biweekly dose, increasing from 6.0 mg up to 4.0 g. Finally, during the maintenance phase, patients were instructed to take 4.0 g of each food allergen continuously, with visits at varied intervals, depending on the clinical outcomes obtained during desensitization. The authors reported a change in the blood levels of sesame-specific IgE and IgG4. No specific comments regarding the clinical outcomes of the patients with sesame allergy were provided, although the authors reported a 40% reduction in the percentage of adverse events per dose in peanut allergy during the initial escalation day to 6% during the maintenance phase and that a similar trend was observed for the other antigens, including sesame. There are no published protocols on sesame allergy.
We report a case of oral desensitization to sesame. The protocol was approved by the Medical Research Ethics Committee of the University of Campinas, Campinas, Brazil (#89404518.0.0000.5404).
